Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2− aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes.
F. Ligorio, L. Provenzano, R. Caputo et al.· EClinicalMedicine· 0 citations
Bone metastases are a major complication of advanced solid tumors and are associated with substantial morbidity and reduced survival. Imaging plays a central role in detection and monitoring, yet conventional modalities and qualitative risk scores remain limited by suboptimal specificity and inter-reader variability. A...
L. Sisca, M. Polito, Emy Sisca et al.· Frontiers in Oncology· 0 citations
Abstract Background Immune checkpoint inhibitors (ICIs) combined with chemotherapy represent a first-line standard across multiple solid tumors; however, the contribution of chemotherapy backbone to the efficacy of chemo-immunotherapy remains uncertain. Methods We conducted a systematic review and network meta-analysis...
L. Sisca, M. Polito, A. Cortellini et al.· The Oncologist· 0 citations
Findings support a role for FMRP as a regulator of SG dynamics and identify the FMRP–G3BP1 axis as a candidate pathway for further investigation in aggressive and treatment-resistant cancers and in tumor adaptation to oxidative stress across distinct cellular contexts and survival programs.
Elena Santonico, Federica Ferrentino, C. Cirotti et al.· Cell Death & Disease· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
